Recomendaciones de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en espondiloartritis axial

Rudwaleit, 2011, The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general, Ann Rheum Dis., 70, 25, 10.1136/ard.2010.133645 Van der Heijde, 2017, 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis, Ann Rheum Dis., 1 Sociedad Española de Reumatología. Grupo de trabajo ESPOGUIA. Guía de Práctica Clínica para el Tratamiento de la Espondiloartritis Axial y la Artritis Psoriásica [monografía en internet]. Madrid: Sociedad Española de Reumatología. 2015. Rojas-Vargas, 2009, First signs and symptoms of spondyloarthritis—data from an inception cohort with a disease course of two years or less (REGISPONSER-Early), Rheumatology (Oxford)., 48, 404, 10.1093/rheumatology/ken506 Ariza-Ariza, 2009, Work disability in patients with ankylosing spondylitis, J Rheumatol., 36, 2512, 10.3899/jrheum.090481 Callhoff, 2015, Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: A meta-analysis, Ann Rheum Dis., 74, 1241, 10.1136/annrheumdis-2014-205322 Van der Heijde, 2005, Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study, Arthritis Rheum., 52, 1205, 10.1002/art.20985 Balazcs, 2016, A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis, BMC Musculoskelet Disord., 17, 426, 10.1186/s12891-016-1275-5 Gratacos, 2016, Etoricoxib in ankylosing spondylitis: Is there a role for active patients refractory to traditional NSAIDs?, Clin Exp Rheumatol., 34, 94 Clegg, 1999, Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study, Arthritis Rheum., 42, 2325, 10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C European Medicines Agency. Ficha técnica de Simponi (golimumab) [consultado 13 Dic 2016]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000992/WC500052368.pdf Heldmann, 2010, Update on biologic therapy in the management of axial spondyloarthritis, Curr Rheumatol Rep., 12, 325, 10.1007/s11926-010-0125-y Baraliakos, 2012, Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis, Rheumatology (Oxford)., 51, 1378, 10.1093/rheumatology/kes026 Juanola Roura, 2011, Documento SER de consenso sobre el uso de terapias biológicas en la espondilitis anquilosante y otras espondiloartritis, excepto la artritis psoriásica, Reumatol Clin., 7, 113, 10.1016/j.reuma.2010.12.002 Desmarais, 2016, Certolizumab pegol for treating axial spondyloarthritis, Expert Opin Biol Ther., 16, 1059, 10.1080/14712598.2016.1205581 Landewe, 2014, Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase3 study, Ann Rheum Dis., 73, 39, 10.1136/annrheumdis-2013-204231 Clowse, 2015, Pregnancy outcomes in subjects exposed to certolizumab pegol, J Rheumatol., 42, 2270, 10.3899/jrheum.140189 Abad Hernández, 2015, Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares, Reumatol Clin., 11, 269, 10.1016/j.reuma.2015.03.009 World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009 [consultado 15 Feb 2017]. Disponible en: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS__FOR _WEB_ 22APRIL2010.pdf European Medicines Agency. Ficha técnica del Infliximab [consultado 16 Oct 2016]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002778/WC500151489.pdf European Medicines Agency. Ficha técnica de Remsima [consultado 25 Ene 2017]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002576/WC500150871.pdf European Medicines Agency. Ficha técnica de Flixabi [consultado 30 Ene 2017]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004020/WC500208356.pdf Yoo, 2013, A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study, Ann Rheum Dis., 72, 1613, 10.1136/annrheumdis-2012-203090 Park, 2013, A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study, Ann Rheum Dis., 72, 1605, 10.1136/annrheumdis-2012-203091 European Medicines Agency. Ficha técnica de Benepali [consultado 31 Ene 2017]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004007/WC500200380.pdf Baeten, 2015, Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis, N Engl J Med., 373, 2534, 10.1056/NEJMoa1505066 Baeten, 2014, Secukinumab, a monoclonal antibody to interleukin-17a, significantly improves signs and symptoms of active ankylosing spondylitis: Results of a 52-week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing, Arthritis Rheumatol., 66, S360 Baraliakos X DA, 2015, Effect of interleukin-17A inhibition on spinal radiographic changes through 2years in patients with active ankylosing spondylitis: results of a phase 3 study with secukinumab. ACR Meeting Abstracts, Arthritis Rheumatol., 67 Hueber, 2012, Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial, Gut., 61, 1693, 10.1136/gutjnl-2011-301668 Poddubnyy, 2014, Ustekinumab for the treatment of patients with active ankylosing spondylitis: Results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS), Ann Rheum Dis., 73, 817, 10.1136/annrheumdis-2013-204248 Pathan, 2013, Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis, Ann Rheum Dis., 72, 1475, 10.1136/annrheumdis-2012-201915 Van der Heijde, 2016, Tofacitinib in patients with ankylosing spondylitis: A phase II, 16-week, randomised, placebo-controlled, dose-ranging study, Ann Rheum Dis., 75, 52, 10.1136/annrheumdis-2016-eular.1847 Haroon, 2013, The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis, Arthritis Rheum., 65, 2645 Barkham, 2009, Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis, Arthritis Rheum., 60, 946, 10.1002/art.24408 Van der Heijde, 2005, Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT), Arthritis Rheum., 52, 582, 10.1002/art.20852 Sieper, 2014, Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: Results from the double-blind, placebo-controlled INFAST study, Part 1, Ann Rheum Dis., 73, 101, 10.1136/annrheumdis-2012-203201 Rudwaleit, 2004, Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis, Ann Rheum Dis., 63, 665, 10.1136/ard.2003.016386 Seo, 2015, Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis, Clin Rheumatol., 34, 1397, 10.1007/s10067-014-2768-y Baraliakos, 2005, Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3years of continuous treatment with infliximab, Arthritis Res Ther., 7, R439, 10.1186/ar1693 Ramiro, 2014, Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort, Ann Rheum Dis., 73, 1455, 10.1136/annrheumdis-2014-205178 Machado, 2014, Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis, Best Pract Res Clin Rheumatol., 28, 711, 10.1016/j.berh.2014.10.004 Cardiel, 2003, Clin Exp Rheumatol., 21, 451 Lukas, 2009, Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis, Ann Rheum Dis., 68, 18, 10.1136/ard.2008.094870 Fernandez-Espartero, 2014, Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme, Ann Rheum Dis., 73, 1350, 10.1136/annrheumdis-2012-202976 Van der Heijde, 2012, Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial, Rheumatology (Oxford)., 51, 1894, 10.1093/rheumatology/kes142 Navarro-Compan, 2016, Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort, Ann Rheum Dis., 75, 874, 10.1136/annrheumdis-2015-207786 Machado, 2011, Endorsement of definitions of disease activity states and improvement scores for the ankylosing spondylitis disease activity score: Results from OMERACT 10, J Rheumatol., 38, 1502, 10.3899/jrheum.110279 Mandl, 2015, EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice, Ann Rheum Dis., 74, 1327, 10.1136/annrheumdis-2014-206971 Ariza-Ariza, 2003, Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis, Arthritis Rheum., 49, 483, 10.1002/art.11197 Kiltz, 2016, Which aspects of health are most important for patients with spondyloarthritis? A Best Worst Scaling based on the ASAS Health Index, Rheumatology (Oxford)., 55, 1771, 10.1093/rheumatology/kew238 Bremander, 2011, Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis, Arthritis Care Res., 63, 550, 10.1002/acr.20408 Haroon, 2015, Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: A population-based study, Ann Intern Med., 163, 409, 10.7326/M14-2470 Genre, 2015, Anti-TNF-alpha therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients, Rheumatol Int., 35, 2069, 10.1007/s00296-015-3314-1 Van Sijl, 2015, Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis, Ann Rheum Dis., 74, 119, 10.1136/annrheumdis-2013-203934 Kiltz, 2012, Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?, Arthritis Care Res., 64, 1415, 10.1002/acr.21688 Boonen, 2015, The burden of non-radiographic axial spondyloarthritis, Semin Arthritis Rheum., 44, 556, 10.1016/j.semarthrit.2014.10.009 Callhoff, 2014, Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: A meta-analysis, Ann Rheum Dis., 74, 1241, 10.1136/annrheumdis-2014-205322 Machado, 2013, Treatment of ankylosing spondylitis with TNF blockers: A meta-analysis, Rheumatol Int., 33, 2199, 10.1007/s00296-013-2772-6 Escalas, 2010, Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: Results of a meta-analysis, Rheumatology (Oxford)., 49, 1317, 10.1093/rheumatology/keq078 Baraliakos, 2014, Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis, Ann Rheum Dis., 73, 710, 10.1136/annrheumdis-2012-202698 Braun, 2017, Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study, Ann Rheum Dis., 76, 1070, 10.1136/annrheumdis-2016-209730 Dougados, 2014, Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: A multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheumatol., 66, 2091, 10.1002/art.38721 Sieper, 2013, Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: Results of a randomised placebo-controlled trial (ABILITY-1), Ann Rheum Dis., 72, 815, 10.1136/annrheumdis-2012-201766 Sieper, 2015, A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis, Arthritis Rheumatol., 67, 2702, 10.1002/art.39257 Rudwaleit, 2008, MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis, Ann Rheum Dis., 67, 1276, 10.1136/ard.2007.073098 Poddubnyy, 2011, Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis, Ann Rheum Dis., 70, 1369, 10.1136/ard.2010.145995 Lie, 2015, The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: Results from a nationwide prospective study, Ann Rheum Dis., 74, 970, 10.1136/annrheumdis-2014-206616 Sepriano, 2016, Effect of comedication with conventional synthetic disease-modifying antirheumatic drugs on retention of tumor necrosis factor inhibitors in patients with spondyloarthritis: A prospective cohort study, Arthritis Rheumatol., 68, 2671, 10.1002/art.39772 Mease, 2016, Discontinuation of biologic therapy in patients with ankylosing spondylitis—Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract], Arthritis Rheumatol., 68 Sepriano, 2017, Efficacy and safety of biological and targeted-synthetic DMARDs: A systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis, RMD open., 3, e000396, 10.1136/rmdopen-2016-000396 Arends, 2011, Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: A prospective longitudinal observational cohort study, Arthritis Res Ther., 13, R94, 10.1186/ar3369 Glintborg, 2010, Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: Results from 8 years’ surveillance in the Danish nationwide DANBIO registry, Ann Rheum Dis., 69, 2002, 10.1136/ard.2009.124446 Fagerli, 2011, Predictors of ASDAS major improvement in patients with ankylosing spondylitis receiving their first TNF inhibitor. Results from a longitudinal observational study, Arthritis Rheum., 63, 166 Maneiro, 2015, Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: Systematic review and meta-analysis, RMD Open., 1, e000017, 10.1136/rmdopen-2014-000017 Haibel, 2008, Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two, Arthritis Rheum., 58, 1981, 10.1002/art.23606 Gremese, 2014, Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis, Rheumatology (Oxford)., 53, 875, 10.1093/rheumatology/ket433 Glintborg, 2016, Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: Results from the Danish nationwide DANBIO registry, Rheumatology (Oxford)., 55, 659, 10.1093/rheumatology/kev392 Sieper, 2012, Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis, Ann Rheum Dis., 71, 700, 10.1136/annrheumdis-2011-200358 Maksymowych, 2015, Biomarkers in axial spondyloarthritis, Curr Opin Rheumatol., 27, 343, 10.1097/BOR.0000000000000180 Baraliakos, 2005, Radiographic progression in patients with ankylosing spondylitis after 2years of treatment with the tumour necrosis factor alpha antibody infliximab, Ann Rheum Dis., 64, 1462, 10.1136/ard.2004.033472 Poddubnyy, 2012, Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis, Arthritis Rheum., 64, 1388, 10.1002/art.33465 Maksymowych, 2009, Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: Evidence of a relationship between inflammation and new bone formation, Arthritis Rheum., 60, 93, 10.1002/art.24132 Maksymowych, 2010, Low-dose infliximab (3mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: A randomized placebo-controlled study, J Rheumatol., 37, 1728, 10.3899/jrheum.091043 Baraliakos, 2016, Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: An observational study, Ann Rheum Dis., 75, 408, 10.1136/annrheumdis-2015-207544 Song, 2011, Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): A 48-week randomised controlled trial, Ann Rheum Dis., 70, 590, 10.1136/ard.2010.139667 Song, 2015, Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3years of continuous treatment with etanercept: Data of the ESTHER trial, Rheumatology (Oxford)., 54, 257, 10.1093/rheumatology/keu263 Van der Heijde, 2008, Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis, Arthritis Rheum., 58, 3063, 10.1002/art.23901 Van der Heijde, 2008, Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept, Arthritis Rheum., 58, 1324, 10.1002/art.23471 Van der Heijde, 2009, Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2years, Arthritis Res Ther., 11, R127, 10.1186/ar2794 Baraliakos, 2014, Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography, Ann Rheum Dis., 73, 1819, 10.1136/annrheumdis-2013-203425 Haroon, 2011, Continuance of non-steroidal anti-inflammatory drugs may reduce radiographic progression in ankylosing spondylitis patients on biological therapy, Arthritis Rheum., 63, 1303 Landewe, 2009, Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine, Ann Rheum Dis., 68, 863, 10.1136/ard.2008.091793 Rudwaleit, 2010, Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy, Arthritis Res Ther., 12, R117, 10.1186/ar3054 Lie, 2011, Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register, Ann Rheum Dis., 70, 157, 10.1136/ard.2010.131797 Dadoun, 2011, Switching between tumour necrosis factor blockers in spondyloarthritis: A retrospective monocentre study of 222 patients, Clin Exp Rheumatol., 29, 1010 Pavelka, 2012, Efficacy of the first and subsequent courses of anti-TNF therapy in patients with ankylosing spondylitis — Results from the Czech National Register ATTRA, Reumatologia., 50, 294 Glintborg, 2013, Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: Results from the Danish nationwide DANBIO registry, Ann Rheum Dis., 72, 1149, 10.1136/annrheumdis-2012-201933 Gulyas, 2014, Real-life experience with switching TNF-alpha inhibitors in ankylosing spondylitis, Eur J Health Econ., 15, S93, 10.1007/s10198-014-0598-0 Braun, 2016, Secukinumab (AIN457) in the treatment of ankylosing spondylitis, Expert Opin Biol Ther., 16, 711, 10.1517/14712598.2016.1167183 Song, 2010, Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial, Arthritis Rheum., 62, 1290, 10.1002/art.27383 Lee, 2008, Etanercept 25mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients, Clin Rheumatol., 27, 179, 10.1007/s10067-007-0674-2 Lee, 2010, Extended dosing of etanercept 25mg can be effective in patients with ankylosing spondylitis: A retrospective analysis, Clin Rheumatol., 29, 1149, 10.1007/s10067-010-1542-z Navarro-Compan, 2011, Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease, Clin Rheumatol., 30, 993, 10.1007/s10067-011-1722-5 Cantini, 2013, Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: A randomized, prospective, long-term, follow-up study, Biologics., 7, 1 Borras-Blasco, 2014, Clinical and economic impact of the use of etanercept 25mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients, Expert Opin Biol Ther., 14, 145, 10.1517/14712598.2014.868433 De Stefano, 2014, Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients, Clin Rheumatol., 33, 707, 10.1007/s10067-013-2372-6 Yates, 2015, Is etanercept 25mg once weekly as effective as 50mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial, J Rheumatol., 42, 1177, 10.3899/jrheum.141335 Morck, 2013, Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: A two-year pilot study, Mediators Inflamm., 2013, 289845, 10.1155/2013/289845 Paccou, 2012, Dosage adjustment of anti-tumor necrosis factor-alpha inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice, J Rheumatol., 39, 1418, 10.3899/jrheum.111337 Zavada, 2015, A tailored approach to reduce dose of anti-TNF drugs is equally effective and less costly than standard dosing in patients with ankylosing spondylitis over two years: A propensity score-matched cohort study, Ann Rheum Dis., 74, 749, 10.1136/annrheumdis-2015-eular.2257 Almirall, 2015, Dose reduction of biological treatment in patients with axial spondyloarthritis in clinical remission: Are there any differences between patients who relapsed and to those who remained in low disease activity?, Rheumatol Int., 35, 1565, 10.1007/s00296-015-3288-z Arends, 2015, Patient-tailored dose reduction of TNF-alpha blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice, Clin Exp Rheumatol., 33, 174 Plasencia, 2015, Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity, J Rheumatol., 42, 1638, 10.3899/jrheum.141128 Zavada, 2016, A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: A propensity score-matched cohort study, Ann Rheum Dis., 75, 96, 10.1136/annrheumdis-2014-205202 Gratacos-Masmitja, 2015, Dose reduction compared with standard dosing for maintenance of remission in patients with spondyloarthropathies and clinical remission with anti-TNF: A randomised real-life trial [abstract], Arthritis Rheumatol., 67 Park, 2016, Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in ankylosing spondylitis, PLoS One., 11, e0168958, 10.1371/journal.pone.0168958 Gonzalez-Alvaro, 2015, Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, Rheumatology (Oxford)., 54, 1200, 10.1093/rheumatology/keu461 De Winter, 2016, Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: A meta-analysis, Arthritis Res Ther., 18, 196, 10.1186/s13075-016-1093-z Braun, 2006, Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial, Ann Rheum Dis., 65, 1147, 10.1136/ard.2006.052878 Regel, 2017, Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: A systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis, RMD Open., 3, e000397, 10.1136/rmdopen-2016-000397 Brandt, 2002, Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab, J Rheumatol., 29, 118 Marzo-Ortega, 2001, Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study, Arthritis Rheum., 44, 2112, 10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H Kruithof, 2005, Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies, Arthritis Rheum., 52, 3898, 10.1002/art.21426 Glintborg, 2011, Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: Results from the nationwide Danish DANBIO registry, Arthritis Rheum., 63, 382, 10.1002/art.30117 Kavanaugh, 2016, Secukinumab for long-term treatment of psoriatic arthritis: 2-year follow-up from a phase 3, randomized, double-blind, placebo-controlled study, Arthritis Care Res., 69, 347, 10.1002/acr.23111 Barreiro-de-Acosta, 2012, Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease, Rev Esp Enferm Dig., 104, 468, 10.4321/S1130-01082012000900004 Paramarta, 2013, Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis, Ann Rheum Dis., 72, 1793, 10.1136/annrheumdis-2012-202245 Mease, 2015, Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis, Arthritis Rheumatol., 67, 914, 10.1002/art.39008 Carron, 2016, Efficacy of Golimumab in patients with active very early peripheral spondyloarthritis. First results from the CRESPA trial. International Congress on Spondyloarthritides (SPA), Clin Exp Rheumatol., 34, 725 Meyer, 2011, Safety and efficacy of anti-tumor necrosis factor alpha therapy in ten patients with recent-onset refractory reactive arthritis, Arthritis Rheum., 63, 1274, 10.1002/art.30272 Brinster, 2017, Anti-TNF treatment of reactive arthritis. A monocentric experience, Joint Bone Spine., 84, 237, 10.1016/j.jbspin.2016.02.022 Rudwaleit, 2016, Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis, Arthritis Care Res., 68, 838, 10.1002/acr.22848 Braun, 2005, Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept, Arthritis Rheum., 52, 2447, 10.1002/art.21197 Lie, 2015, The effect of TNF inhibitor treatment on occurrence of anterior uveitis in ankylosing spondylitis: Results from the Swedish Biologics Register, Arthritis Rheumatol, 67, 1271 Guignard, 2006, Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: A retrospective study, Ann Rheum Dis., 65, 1631, 10.1136/ard.2006.052092 Braun, 2011, Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial, Arthritis Rheum., 63, 1543, 10.1002/art.30223 Braun, 2007, Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents, Arthritis Rheum., 57, 639, 10.1002/art.22669 Sandborn, 2012, Ustekinumab induction and maintenance therapy in refractory Crohn's disease, N Engl J Med., 367, 1519, 10.1056/NEJMoa1203572 Deodhar, 2015, Safety and tolerability of secukinumab in patients with active ankylosing spondylitis: Pooled safety analysis of two phase 3, randomized, controlled trials [abstract] ACR/ARHP Annual Meeting, Arthritis Rheumatol., 67 Sherlock, 2012, IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells, Nat Med., 18, 1069, 10.1038/nm.2817